Trial Profile
Retrospective cohort study of resistance associated substitutions and clinical course in Glecaprevir(GLE)/Pibrentasvir(PIB) treatment to hepatitis C virus
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2019
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 May 2019 Status changed from not yet recruiting to recruiting.
- 03 Nov 2017 New trial record